Table 1.
Clinical variables of the 90 coronary artery disease patients with or without metabolic syndrome
| Items | All patients (n=90) | No metabolic syndrome group (n=37) | Metabolic syndrome group (n=53) | P |
|---|---|---|---|---|
| Age (years) | 65.59±8.63 | 66.70±8.78 | 64.81±8.52 | 0.309 |
| Height (cm) | 161.51±7.79 | 162.35±6.09 | 160.92±8.79 | 0.395 |
| Body weight (kg) | 68.37±11.94 | 65.05±9.81 | 70.69±12.80 | 0.027* |
| Waist circumference (cm) | 92.88±10.09 | 87.81±8.57 | 96.42±9.61 | <0.001* |
| BMI (kg/m2) | 26.12±3.49 | 24.63±3.06 | 27.15±3.43 | 0.001* |
| Systolic blood pressure (mmHg) | 131.80±19.44 | 124.14±14.20 | 137.15±20.89 | 0.001* |
| Diastolic blood pressure (mmHg) | 71.96±9.57 | 70.76±8.59 | 72.79±10.19 | 0.323 |
| Total cholesterol (mg/dL) | 162.61±33.69 | 161.32±32.58 | 163.51±34.72 | 0.764 |
| Triglyceride (mg/dL) | 119.00 (89.75-168.00) | 101.00 (77.00-125.00) | 148.00 (94.50-219.50) | <0.001* |
| HDL-C (mg/dL) | 44.60±11.86 | 49.65±12.58 | 41.08±10.03 | 0.001* |
| LDL-C (mg/dL) | 93.93±27.19 | 91.65±26.46 | 95.53±27.83 | 0.508 |
| Fasting glucose (mg/dL) | 108.00 (94.75-142.00) | 98.00 (90.00-115.00) | 129.00 (104.50-169.50) | <0.001* |
| Blood urea nitrogen (mg/dL) | 16.00 (13.00-19.00) | 15.00 (12.50-17.00) | 17.00 (13.00-20.50) | 0.044* |
| Creatinine (mg/dL) | 1.10 (0.90-1.30) | 1.00 (0.90-1.20) | 1.10 (0.90-1.45) | 0.066 |
| eGFR (mL/min) | 67.94±19.59 | 73.86±14.05 | 63.81±21.85 | 0.016* |
| CRP (mg/dL) | 0.19 (0.14-0.27) | 0.17 (0.14-0.21) | 0.24 (0.15-0.36) | 0.010* |
| Insulin (uIU/mL) | 10.65 (6.80-19.62) | 9.33 (5.96-16.55) | 13.21 (9.08-21.61) | 0.040* |
| HOMA-IR | 3.54 (2.03-6.46) | 2.21 (1.42-4.19) | 4.23 (2.88-8.49) | 0.002* |
| ANGPTL3 (ng/mL) | 240.31 (164.40-294.29) | 200.32 (116.17-271.33) | 264.02 (191.60-346.31) | 0.001* |
| Female, n (%) | 23 (25.6) | 6 (16.2) | 17 (32.1) | 0.090 |
| Hypertension, n (%) | 73 (81.1) | 24 (64.9) | 49 (92.5) | 0.001* |
| Diabetes, n (%) | 44 (48.9) | 9 (24.3) | 35 (66.0) | <0.001* |
| ACE inhibitor use, n (%) | 24 (26.7) | 6 (16.2) | 18 (34.0) | 0.061 |
| ARB use, n (%) | 37 (41.1) | 13 (35.1) | 24 (45.3) | 0.336 |
| β-blocker use, n (%) | 52 (71.2) | 19 (51.4) | 33 (62.3) | 0.302 |
| CCB use, n (%) | 32 (35.6) | 10 (27.0) | 22 (41.5) | 0.158 |
| Statin use, n (%) | 67 (74.4) | 26 (70.3) | 41 (77.4) | 0.448 |
| Fibrate use, n (%) | 13 (14.4) | 5 (13.5) | 8 (15.1) | 0.834 |
*P<0.05 was considered statistically significant. Values for continuous variables given as means±SD and are test by Student’s t-test; variables not normally distributed given as medians and interquartile range and are test by Mann-Whitney U test; values are presented as, n (%) and analysis was done using the Chi-square test. HDL-C: High density lipoprotein cholesterol, LDL-C: Low density lipoprotein cholesterol, eGFR: Estimated glomerular filtration rate, HOMA-IR: Homeostasis model assessment of insulin resistance, ANGPTL3: Angiopoietin-like protein 3, ACE: Angiotensin-converting enzyme, ARB: Angiotensin-receptor blocker, CCB: Calcium-channel blocker, SD: Standard deviation, BMI: Body mass index